495 results on '"Dufour, Jean-Francois"'
Search Results
2. Spatial lipidomics reveals zone-specific hepatic lipid alteration and remodeling in metabolic dysfunction-associated steatohepatitis
3. Regional Differences in Clinical Presentation and Prognosis of Patients With Post–Sustained Virologic Response Hepatocellular Carcinoma
4. Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab–bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study
5. Validation of the Blood Test MACK-3 for the Noninvasive Diagnosis of Fibrotic Nonalcoholic Steatohepatitis: An International Study With 1924 Patients
6. Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of pre-cirrhotic fibrosis due to non-alcoholic steatohepatitis
7. A global research priority agenda to advance public health responses to fatty liver disease
8. Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis
9. Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study
10. Characterisation of hepatic lipid signature distributed across the liver zonation using mass spectrometry imaging
11. L’aéronautique chinoise : bientôt dans la cour des grands?
12. NAFLD and NASH biomarker qualification in the LITMUS consortium – Lessons learned
13. Spezifische Therapie – neue Medikamente
14. Molecular Markers of Response to Anti-PD1 Therapy in Advanced Hepatocellular Carcinoma
15. Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma
16. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials
17. The MELD upgrade exception: a successful strategy to optimize access to liver transplantation for patients with high waiting list mortality
18. Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance
19. Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests
20. The global epidemiology of nonalcoholic steatohepatitis (NASH) and associated risk factors–A targeted literature review
21. Redefining fatty liver disease: an international patient perspective
22. Machine learning approaches to enhance diagnosis and staging of patients with MASLD using routinely available clinical information
23. Auto-aggressive CXCR6+ CD8 T cells cause liver immune pathology in NASH
24. NASH limits anti-tumour surveillance in immunotherapy-treated HCC
25. Nuclear deformation mediates liver cell mechanosensing in cirrhosis
26. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement
27. Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis
28. Incidence of hepatocellular carcinoma in HIV/HBV-coinfected patients on tenofovir therapy: Relevance for screening strategies
29. Genetic immune and inflammatory markers associated with diabetes in solid organ transplant recipients
30. Sofosbuvir/velpatasvir for 12 weeks in genotype 1–4 HCV-infected liver transplant recipients
31. High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1–6 patients without cirrhosis
32. Genetic and clinic predictors of new onset diabetes mellitus after transplantation
33. Corrigendum to: “Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort☆” [J Hepatol (2020) 505–515]
34. Other Extrahepatic Manifestations of Hepatitis C Virus Infection (Pulmonary, Idiopathic Thrombocytopenic Purpura, Nondiabetes Endocrine Disorders)
35. A Dynamic Model of the Type-2 Inositol Trisphosphate Receptor
36. Un terzo gigante dell’aeronautica mondiale?
37. Appropriazione ad alta velocità
38. I futuri 'big' dell’automobile saranno cinesi?
39. Nel cuore delle nuove tecnologie
40. I nuovi riferimenti degli elettrodomestici
41. La battaglia delle telecomunicazioni
42. L’evoluzione del mastodonte dell’elettronica
43. I nuovi padroni dell’industria tessile cinese
44. Conclusioni Quali risposte alle sfide cinesi?
45. Introduzione Gli inizi di un cambiamento radicale
46. Majors petrolifere particolari
47. I nuovi esploratori
48. Supplementary Data from First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma
49. Data from First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma
50. Normalization of lipid oxidation defects arising from hypoxia early posthepatectomy prevents liver failure in mouse
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.